Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA has accepted United Therapeutics' new drug application for ralinepag, a once-daily oral prostacyclin receptor agonist for pulmonary arterial hypertension (PAH). Backed by phase 3 ADVANCE OUTCOMES trial data, the drug cut the risk of clinical worsening by 55% versus placebo. A regulatory decision is expected by June 24, 2027.
The FDA has officially accepted United Therapeutics' new drug application (NDA) for ralinepag, a once-daily oral prostacyclin receptor agonist being developed for pulmonary arterial hypertension (PAH) — a progressive, life-threatening condition affecting hundreds of thousands worldwide. The NDA is backed by data from the global phase 3 ADVANCE OUTCOMES trial, published in The Lancet in August 2026, which enrolled 687 adults across 30 countries.
The trial showed ralinepag significantly reduced the risk of clinical worsening events — including death, hospitalization, and disease progression — by 55% compared to placebo (HR = 0.45). Patients also showed meaningful improvements in 6-minute walk distance and NT-proBNP levels over 28 weeks. The drug's safety profile was consistent with known prostacyclin-related side effects, with no increase in serious adverse events.
Key Takeaways:
Why it matters: Current PAH therapies are often burdensome — requiring injections, pumps, or multiple daily doses — limiting real-world adherence. If approved, ralinepag's once-daily oral convenience could meaningfully improve patient adherence and outcomes, potentially reshaping how PAH is managed earlier in the disease course. The FDA's target action date is June 24, 2027.
